Literature DB >> 22672212

Salivary gland hypofunction induced by activation of innate immunity is dependent on type I interferon signaling.

Seshagiri-Rao Nandula1, Paromita Dey, Kathryn L Corbin, Craig S Nunemaker, Harini Bagavant, Umesh S Deshmukh.   

Abstract

BACKGROUND: Activation of innate immunity through polyinosinic:polycytidylic acid [poly(I:C)] causes acute salivary gland hypofunction. As a major consequence of poly(I:C) treatment is type I interferon (IFN) production, this study was undertaken to investigate their role in salivary gland dysfunction.
METHODS: Different strains of mice deficient in either interferon alpha receptor (IFNAR1(-/-)) or IL-6(-/-), or IL-10(-/-), or EBI3(-/-) were treated with poly(I:C). Salivary gland function was determined by measuring pilocarpine-induced saliva volume. Gene expression levels were measured by real-time PCR. Ca(2+) mobilization studies were performed using ex-vivo acinar cells.
RESULTS: A single injection of poly(I:C) rapidly induced salivary gland hypofunction in wild-type B6 mice (41% drop in saliva volumes compared to PBS-treated mice). In contrast, the loss of function in poly(I:C)-treated IFNAR(-/-) mice was only 9.6%. Gene expression analysis showed reduced levels of Il-6, Il-10, and Il-27 in submandibular glands of poly(I:C)-treated IFNAR(-/-) mice. While salivary gland dysfunction in poly(I:C)-treated IL-10(-/-) and EBI3(-/-) mice was comparable to wild-type mice, the IL-6(-/-) mice were more resistant, with only a 21% drop in function. Pilocarpine-induced Ca(2+) flux was significantly suppressed in acinar cells obtained from poly(I:C)-treated wild-type mice.
CONCLUSIONS: Our data demonstrate that a combined action of type I IFNs and IL-6 contributes toward salivary gland hypofunction. This happens through interference with Ca(2+) mobilization within acinar cells. Thus, in acute viral infections and diseases like Sjögren's syndrome, elevated levels of type I IFNs and IL-6 can directly affect glandular function.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22672212      PMCID: PMC3443546          DOI: 10.1111/j.1600-0714.2012.01181.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  33 in total

1.  Primary Sjögren's syndrome (pSS): subjective symptoms and salivary findings.

Authors:  A M Pedersen; J Reibel; B Nauntofte
Journal:  J Oral Pathol Med       Date:  1999-08       Impact factor: 4.253

Review 2.  Regulation of fluid and electrolyte secretion in salivary gland acinar cells.

Authors:  James E Melvin; David Yule; Trevor Shuttleworth; Ted Begenisich
Journal:  Annu Rev Physiol       Date:  2005       Impact factor: 19.318

3.  A novel fluorescence imaging approach for comparative measurements of pancreatic islet function in vitro.

Authors:  Kathryn L Corbin; Thomas E Hall; Ruth Haile; Craig S Nunemaker
Journal:  Islets       Date:  2011-01-01       Impact factor: 2.694

Review 4.  Activation of the type I interferon pathway in primary Sjogren's syndrome.

Authors:  Clio P Mavragani; Mary K Crow
Journal:  J Autoimmun       Date:  2010-07-31       Impact factor: 7.094

5.  Cevimeline-induced monophasic salivation from the mouse submandibular gland: decreased Na+ content in saliva results from specific and early activation of Na+/H+ exchange.

Authors:  Yusuke Kondo; Tetsuji Nakamoto; Taro Mukaibo; Manami Kidokoro; Chihiro Masaki; Ryuji Hosokawa
Journal:  J Pharmacol Exp Ther       Date:  2011-01-14       Impact factor: 4.030

Review 6.  Xerostomia: an update for clinicians.

Authors:  M S Hopcraft; C Tan
Journal:  Aust Dent J       Date:  2010-09       Impact factor: 2.291

7.  Reduced methacholine-induced submandibular salivary secretion in rats with experimental periodontitis.

Authors:  Mariano Amer; Juan C Elverdin; Javier Fernández-Solari; Vanina A Medina; Ana P Chiarenza; María I Vacas
Journal:  Arch Oral Biol       Date:  2010-12-08       Impact factor: 2.633

8.  Transcriptional activation of the mouse Mx gene by type I interferon.

Authors:  P Staeheli; P Danielson; O Haller; J G Sutcliffe
Journal:  Mol Cell Biol       Date:  1986-12       Impact factor: 4.272

9.  Carbachol, substance P, and phorbol ester promote the tyrosine phosphorylation of protein kinase C delta in salivary gland epithelial cells.

Authors:  S P Soltoff; A Toker
Journal:  J Biol Chem       Date:  1995-06-02       Impact factor: 5.157

10.  Functional role of type I and type II interferons in antiviral defense.

Authors:  U Müller; U Steinhoff; L F Reis; S Hemmi; J Pavlovic; R M Zinkernagel; M Aguet
Journal:  Science       Date:  1994-06-24       Impact factor: 47.728

View more
  18 in total

Review 1.  The NZB/W F1 mouse model for Sjögren's syndrome: A historical perspective and lessons learned.

Authors:  Harini Bagavant; Aleksandra Michrowska; Umesh S Deshmukh
Journal:  Autoimmun Rev       Date:  2020-10-22       Impact factor: 9.754

Review 2.  Innate immunity in Sjögren's syndrome.

Authors:  Jeremy Kiripolsky; Liam G McCabe; Jill M Kramer
Journal:  Clin Immunol       Date:  2017-04-08       Impact factor: 3.969

3.  Toll-like receptor 3 stimulation promotes Ro52/TRIM21 synthesis and nuclear redistribution in salivary gland epithelial cells, partially via type I interferon pathway.

Authors:  N C Kyriakidis; E K Kapsogeorgou; V C Gourzi; O D Konsta; G E Baltatzis; A G Tzioufas
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

4.  Type I interferon receptor deficiency prevents murine Sjogren's syndrome.

Authors:  B M Szczerba; P D Rybakowska; P Dey; K M Payerhin; A B Peck; H Bagavant; U S Deshmukh
Journal:  J Dent Res       Date:  2013-03-26       Impact factor: 6.116

5.  Agonist-induced 4-1BB activation prevents the development of Sjӧgren's syndrome-like sialadenitis in non-obese diabetic mice.

Authors:  Jing Zhou; Bo Ra You; Qing Yu
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-11-15       Impact factor: 5.187

6.  Protocols for Experimental Sjögren's Syndrome.

Authors:  Harini Bagavant; Umesh S Deshmukh
Journal:  Curr Protoc Immunol       Date:  2020-12

Review 7.  The Role of Interferons in the Pathogenesis of Sjögren's Syndrome and Future Therapeutic Perspectives.

Authors:  Nicoletta Del Papa; Antonina Minniti; Maurizio Lorini; Vincenzo Carbonelli; Wanda Maglione; Francesca Pignataro; Nicola Montano; Roberto Caporali; Claudio Vitali
Journal:  Biomolecules       Date:  2021-02-09

Review 8.  The clinical relevance of animal models in Sjögren's syndrome: the interferon signature from mouse to man.

Authors:  Naomi I Maria; Petra Vogelsang; Marjan A Versnel
Journal:  Arthritis Res Ther       Date:  2015-07-03       Impact factor: 5.156

9.  Assessment of the effect of interferon-beta1a therapy on thyroid and salivary gland functions in patients with multiple sclerosis using quantitative salivary gland scintigraphy.

Authors:  Seval Erhamamcı; Bahriye Horasanlı; Ayşe Aktaş
Journal:  Mol Imaging Radionucl Ther       Date:  2014-06-05

10.  Hepatitis Delta Virus Detected in Salivary Glands of Sjögren's Syndrome Patients and Recapitulates a Sjögren's Syndrome-Like Phenotype in Vivo.

Authors:  Melodie L Weller; Matthew R Gardener; Zoe C Bogus; Michael A Smith; Elisa Astorri; Drew G Michael; Donald A Michael; Changyu Zheng; Peter D Burbelo; Zhennan Lai; Paul A Wilson; William Swaim; Beverly Handelman; Sandra A Afione; Michele Bombardieri; John A Chiorini
Journal:  Pathog Immun       Date:  2016-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.